Early access to study drug for serious conditions
Treatments studied
Part of Heart & circulation clinical trials.
This program provides early access to a Novartis study drug for patients with serious or life-threatening conditions who have no other treatment options. It aims to help patients who cannot join a clinical trial.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a serious or life-threatening condition.
- There must be no other available treatment that works for you.
- Your doctor must request this program for you.
- You cannot be eligible for a clinical trial of this drug.
- The request must be allowed by your country's laws.
- The potential benefit must outweigh the risks for you.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial tests pelacarsen (TQJ230), a medication that lowers a blood fat called lipoprotein(a), to see if it slows progression of calcific aortic valve stenosis. It may help people whose valve narrowing is starting to become more severe, especially when their lipoprotein(a) level is high.
This program provides access to atrasentan for people with serious or life-threatening conditions who have no other treatment options and cannot join a clinical trial.
This program provides early access to two experimental cancer drugs, botensilimab and balstilimab, for patients with serious or life-threatening conditions who have no other treatment options and cannot join a clinical trial.
This program provides access to an experimental medicine called alpelisib (also known as BYL719) for people with serious conditions who have no other treatment options and cannot participate in clinical trials. If a licensed doctor requests it, and you meet the criteria, you may be able to receive this medicine through a managed access program.
This program lets doctors request an unapproved drug for patients with serious, life-threatening diseases when no other good options exist. It's a way to get the medicine outside of a clinical trial.
This program provides access to an investigational medication called eltrombopag for people with serious or life-threatening conditions who have no other good treatment options. It is only available through a doctor's formal request and is not part of a clinical trial.
Hear when a new Atherosclerotic Cardiovascular Disease (ASCVD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.